Theravance Biopharma, Inc. (TBPH) P/E Ratio History
Historical price-to-earnings valuation from 2022 to 2025
Loading P/E history...
TBPH Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Theravance Biopharma, Inc. (TBPH) trades at a price-to-earnings ratio of -14.8x, with a stock price of $17.02 and trailing twelve-month earnings per share of $0.57.
The current P/E is 218% below its 5-year average of 12.6x. Over the past five years, TBPH's P/E has ranged from a low of 0.9x to a high of 46.0x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, TBPH trades at a 166% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, TBPH trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our TBPH DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
TBPH P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 6.9 | 0.67 | +817%Best | |
| $930M | 147.8 | - | +107% | |
| $243M | 4.9Lowest | 4.84 | +49% | |
| $102B | 6.7 | 0.47Best | +348% | |
| $536B | 38.4 | - | -58% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
TBPH Historical P/E Data (2022–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | $14.60 | $0.57 | 25.6x | +104% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $11.03 | $0.24 | 46.0x | +266% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $10.35 | $11.30 | 0.9x | -93% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $10.85 | $11.47 | 0.9x | -92% |
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $11.22 | $11.48 | 1.0x | -92% |
| FY2022 Q3 | Fri Sep 30 2022 00:00:00 GM | $10.14 | $11.26 | 0.9x | -93% |
Average P/E for displayed period: 12.6x
See TBPH's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TBPH Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TBPH vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTBPH — Frequently Asked Questions
Quick answers to the most common questions about buying TBPH stock.
Is TBPH stock overvalued or undervalued?
TBPH trades at -14.8x P/E, below its 5-year average of 12.6x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does TBPH's valuation compare to peers?
Theravance Biopharma, Inc. P/E of -14.8x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is TBPH's PEG ratio?
TBPH PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2022-2025.